Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.64 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | BCKDK | O14874 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31053341 | 0.92 | BCKDK (0.60) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL18940219 | 0.92 | PRNP (0.70) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL18940199 | 0.87 | HTT (0.67) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL29768647 | 0.86 | HTT (0.60) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL18940248 | 0.85 | PRNP (0.58) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL29431544 | 0.85 | PRNP (0.58) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL29670217 | 0.84 | PRNP (0.60) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL18940192 | 0.84 | PRNP (0.60) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL29670015 | 0.83 | PRNP (0.58) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL18940245 | 0.83 | PRNP (0.58) | PRNPTSHRMAPK1PPARGHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364222-B2 | Combination therapy for treatment of cancer | G1 THERAPEUTICS, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20190321332-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364222-B2 | Combination therapy for treatment of cancer | CDK4, CDK6, CCND1 | PRNP 4873/4885TSHR 1263/4885MAPK1 1477/4885 |
| US-20190321332-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | CDK4, CDK6, CCND1 | PRNP 4873/4885TSHR 1263/4885MAPK1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.